Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer.

McEntee MF, Ziegler C, Reel D, Tomer K, Shoieb A, Ray M, Li X, Neilsen N, Lih FB, O'Rourke D, Whelan J.

Am J Pathol. 2008 Jul;173(1):229-41. doi: 10.2353/ajpath.2008.070989. Epub 2008 Jun 13.


Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.

Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM, Chen YQ.

Carcinogenesis. 2012 Feb;33(2):404-12. doi: 10.1093/carcin/bgr290. Epub 2011 Dec 8.


Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.

Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ.

Clin Cancer Res. 2006 Aug 1;12(15):4662-70.


Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.

Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB.

Prostate. 2001 May 1;47(2):102-10.


Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.

Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D.

Clin Cancer Res. 2004 Dec 15;10(24):8728-34.


Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.

Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM.

Cancer Res. 2000 Nov 1;60(21):6134-41.


Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression.

Friedrichs W, Ruparel SB, Marciniak RA, deGraffenried L.

Nutr Cancer. 2011;63(5):771-7. doi: 10.1080/01635581.2011.570892. Epub 2011 Jun 11.


Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.

Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC.

Cancer Res. 2004 Mar 15;64(6):2212-21.


Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes.

Kelavkar UP, Hutzley J, McHugh K, Allen KG, Parwani A.

Neoplasia. 2009 Jul;11(7):692-9.


Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.

Nakashiro K, Hara S, Shinohara Y, Oyasu M, Kawamata H, Shintani S, Hamakawa H, Oyasu R.

Am J Pathol. 2004 Aug;165(2):533-40.


Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice.

Rose DP, Connolly JM, Rayburn J, Coleman M.

J Natl Cancer Inst. 1995 Apr 19;87(8):587-92.


Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.

Kukuk D, Reischl G, Raguin O, Wiehr S, Judenhofer MS, Calaminus C, Honndorf VS, Quintanilla-Martinez L, Schönberger T, Duchamp O, Machulla HJ, Pichler BJ.

J Nucl Med. 2011 Oct;52(10):1654-63. doi: 10.2967/jnumed.110.086702. Epub 2011 Aug 22.


The biology of hormone refractory prostate cancer. Why does it develop?

Isaacs JT.

Urol Clin North Am. 1999 May;26(2):263-73. Review.


Supplemental Content

Support Center